uniQure N.V. QURE | NASDAQ
After Hours
Company Overview:
10 Year QURE Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
Get 3 months FREE!
QURE Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for QURE
Based on past 10-year performance, here are QURE growth metrics:
Share price CAGR of +1.33%
Dividend CAGR of +0%
Using QURE CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| QURE (DRIP) | QURE - No DRIP | |
|---|---|---|
| Current Price | $21.33 | $21.33 |
| Start Shares | 468.82 | 468.82 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 468.82 | 468.82 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $24.02 | $21.33 |
| Total Dividends | $0 | $0 |
| Final Value | $11,263 | $10,000 |
NOTE: Above numbers are our estimate based on QURE's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Get 3 months FREE!
Company Info
uniQure N.V. (QURE) had its IPO on 2014-02-05, and is trader on NASDAQ stock exchange.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE website: https://www.uniqure.com
Get Full Access to All Reports with DRIPCalc PRO
Get 3 months FREE!
